Clinical Trial

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Study acronym: SPORADIC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-23; most recent amendment 2026-02-09.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT06656598
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Stage III NSCLC
Enrollment 152 participants
Start Date 2025-11-07
Primary Completion 2028-09 (estimated)
Study Completion 2032-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11